Nonetheless, some conclusions may still be drawn on the possibility of mitigating the expenditure for GnRH agonists when these second-line medications are indicated in women with progestogen-resistant endometriosis (Table I and Fig. 2). The gene discussed is GNRH1; the disease is endometriosis.